Document:

EX-10.1

SeraCare Life Sciences Awarded Multiple Contracts from the CDC and NIH to Support HIV Research

and the Accuracy of HIV Testing

-Total US Government funded dollars awarded to SeraCare exceeds $35 million over the past two

years -

MILFORD, MA, September 29, 2009—SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced that
the Company has been awarded two new contracts from the Centers for Disease Control (CDC) and the
National Institutes of Health (NIH) and that a third existing contract has been expanded by the NIH
to support federally-funded HIV research and testing. These contracts represent a combined $10.8
million in new funding if all options are exercised over the life of the contracts.

“The government sector is an important customer of our services business and these recent awards
demonstrate SeraCare’s fundamental role in the support of government-sponsored research projects
and, specifically, our leadership position in providing the highest quality services in support of
HIV research and testing,” said Susan Vogt, President and Chief Executive Officer of SeraCare Life
Sciences. “Moreover, we believe these types of projects may increase given the influx of federal
stimulus dollars for government sponsored research.”

Under a new contract awarded by the Centers for Disease Control (CDC) as part of the CDC’s HIV-1
Rapid Test Proficiency Program, SeraCare will support efforts to ensure that laboratories
performing HIV-1 assays are achieving accurate results. The Company will provide well characterized
HIV-1 positive and negative plasma and will test, dispense and distribute panels to approximately
650 laboratories participating in this performance evaluation program, which is used as a
self-assessment tool for facilities performing HIV-1 rapid testing.. The five-year contract is
valued at over $3.6 million if all options are exercised by the CDC.

Under a second new contract awarded by PPD, Inc. to support the NIH’s Division for HIV Clinical
Research Support Services, SeraCare will collect, characterize, assemble and distribute a
comprehensive panel of current worldwide HIV strains. These efforts are designed to establish a
standardized set of viral reagents to help monitor and update blood screening and diagnostic
assays—activities that play a critical role in insuring that the world’s blood supply is safe—and
to assist in the development of vaccines for HIV. The 15 month contract is valued at $2 million.

Under an expanded, existing contract with the NIH to support the National Heart, Lung, and Blood
Institute Biologic Specimen Repository, Contract #N01-HB-87144, SeraCare will support the growth
of the repository and quality control the historic AIDS and AIDS-related studies in the collection
in preparation for anticipated broader use. The $5.2 million expansion increases the remaining
value of the contract over the next two years to $6.3 million.

About SeraCare Life Sciences:

SeraCare serves the global life sciences industry by providing vital products and services to
facilitate the discovery, validation and production of human diagnostics and therapeutics.
SeraCare’s innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular
biomarkers, biobanking and contract research services. SeraCare’s quality systems, scientific
expertise and state-of-the-art facilities support its customers in meeting the stringent
requirements of the highly regulated life sciences industry.

Forward-Looking Statements:

This press release contains disclosures that are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. All
statements regarding our expected future financial position, results of operations, cash flows,
dividends, financing plans, business strategy, budget, projected costs or cost savings, capital
expenditures, competitive positions, growth opportunities for existing products or products under
development, plans and objectives of management for future operations and markets for stock are
forward-looking statements. In addition, forward-looking statements include statements in which we
use words such as “expect,” “believe,” “anticipate,” “intend,” or similar expressions. Although we
believe the expectations reflected in such forward-looking statements are based on reasonable
assumptions, we cannot assure you that these expectations will prove to have been correct, and
actual results may differ materially from those reflected in the forward-looking statements.
Factors that could cause our actual results to differ from the expectations reflected in the
forward-looking statements in this press release include, but are not limited to, failure to
maintain proper inventory levels, availability of financing, covenant limitations in our existing
credit facility, reductions or terminations of government or other contracts, interruption in our
supply of products or raw materials, actions of SeraCare’s competitors and changes in the
regulatory environment. Many of these factors are beyond our ability to control or predict.

Contact Information:

SeraCare Life Sciences, Inc.

Gregory A. Gould, 508-244-6400

Chief Financial Officer

—or—

MacDougall Biomedical Communications

Sarah Cavanaugh, 781-235-3060

Investor RelationsEX-10.01

September 23, 2009

Mr. Liam E. McGee

4424 Fox Brook Lane

Charlotte, NC 28211

Dear Liam:

	 	 	      I am pleased to confirm the terms of your employment with The Hartford Financial Services
Group, Inc. (“HFSG”).

1. Effective Date. October 1, 2009.

 

2. Position. On the Effective Date, you will begin to serve in the Tier 1 position of Chairman
of the Board of Directors and Chief Executive Officer of HFSG. In that capacity, you will report
directly (and only) to the Board of Directors and have all of the customary authorities, duties and
responsibilities that accompany these positions.

 

3. Salary. Your initial cash salary will be $1,100,000 per year ($45,833 per semi-monthly pay
period).

 

4. Deferred Units. In addition to your cash salary, as part of your annual compensation, you
will be eligible to receive semi-monthly awards of Deferred Units under The Hartford Deferred Stock
Unit Plan (“Plan”). You will be issued these awards, subject to the terms of the Plan (as amended
to provide for the payment of Deferred Units in three equal installments after the first, second
and third anniversaries of the applicable Grant Date under the Plan), at an initial rate of
$4,400,000 per year ($183,333 per semi-monthly pay period).

5. Annual Long-Term Award. For the 2010 year, you will receive a long-term incentive award of
$2,700,00 in the form of Restricted Units under the Plan, with such award to be made at the time
that HFSG makes its long-term incentive awards to other employees (anticipated to be late February
2010). Such award shall be subject to the terms of the Plan and shall vest on the third
anniversary of the award date (or on such other dates or events as provided in the Plan), provided
that you are then employed by HFSG, and shall be payable to you as provided in the Plan, to the
extent permissible under applicable law and U.S. Department of the Treasury regulations issued in
connection with the Troubled Asset Relief Program (“TARP”). For calendar years subsequent to 2010,
you will receive long-term incentive awards as may be determined by the independent members of the
HFSG Board of Directors in their discretion (including performance criteria that such members may
determine in consultation with the Special Master for TARP Executive Compensation), with an initial
target award in the amount of $2,700,000, which shall vest and be payable to you as provided in the
Plan, to the extent permissible under applicable law and U.S. Department of the Treasury
regulations issued in connection with TARP.

6. Benefits. Subject to the limits of this letter and the Emergency Economic Stabilization Act
of 2008, as amended by the American Recovery and Reinvestment Act of 2009 and as such Act may be
further amended, and rules, regulations and guidance promulgated by the U.S. Department of the
Treasury or any other governmental authority thereunder (together, and as in effect from time to
time, “EESA”), you will be entitled to benefits consistent with those made available to other
senior executives of HFSG and reimbursement of reasonable relocation and business expenses, in each
case in accordance with applicable HFSG policies as in effect from time to time.

7. Executive Compensation Standards. Any compensation paid or awarded to you is subject to
recovery or “clawback” by HFSG if the payments or awards were based on materially inaccurate
financial statements or any other materially inaccurate performance metric criteria (all within the
meaning of, and to the full extent necessary to comply with,EESA). You will not be entitled to any
tax gross-up from HFSG or its affiliates. In addition, while either you or HFSG may terminate your
employment at any time for any legal reason, you will not be entitled to any severance or other
golden parachute payment to the extent prohibited by EESA. You agree to provide HFSG with 90 days
notice of any intention to deliver a letter of voluntary resignation. After HFSG is no longer
subject to restrictions on executive compensation under EESA, the independent members of the Board
of Directors will, in their discretion, consider appropriate changes to your employment
arrangements and compensation package taking into account the compensation opportunities and
employment practices afforded CEOs of comparable organizations as well as HFSG’s business
circumstances and strategy at that time.

8. Indemnification and Cooperation. During and after your employment, HFSG will indemnify you
in your capacity as a present or former director, officer, employee or agent of HFSG to the fullest
extent permitted by applicable law, including the laws of Delaware, and HFSG’s certificate of
incorporation and by-laws as to any third-party action against you. In addition, HFSG will provide
you with director and officer liability insurance coverage (including
post-termination/post-director service tail coverage) on the same basis as it does for HFSG’s other
executive officers and directors. HFSG agrees to cause any successor to all or substantially all of
the business or assets (or both) of HFSG to assume expressly in writing and to agree to perform all
of the obligations of HFSG in this paragraph.

You agree (whether during or after your employment with HFSG) to reasonably cooperate with
HFSG in connection with any litigation or regulatory matter or with any government authority on any
matter, in each case, pertaining to HFSG and with respect to which you may have relevant knowledge,
provided that, in connection with such cooperation, HFSG will reimburse your reasonable expenses
and you shall not be required to act against your own legal interests.

9. Tax Matters. This letter agreement is intended to comply with the requirements of Section
409A of the Internal Revenue Code of 1986 (“Section 409A”). To the extent any taxable expense
reimbursement or in-kind benefits under paragraph 6 or 8 is subject to Section 409A, the amount
thereof eligible in one taxable year shall not affect the amount eligible for any other taxable
year, in no event shall any expenses be reimbursed after the last day of the taxable year following
the taxable year in which you incurred such expenses and in no event shall any right to
reimbursement or receipt of in-kind benefits be subject to liquidation or exchange for another
benefit. Each payment under this letter will be treated as a separate payment for purposes of
Section 409A.

10. Non-competition and non-solicitation. In consideration for your employment and the terms
hereof, and to protect against the risk that, given the extensive knowledge of HFSG’s operations
that you will acquire during your employment, HFSG’s confidential information and trade secrets
would unavoidably be disclosed to your new employer if you were to become employed with a competing
business, you agree:

(a) while employed by HFSG and for a one year period following a voluntary termination of
your employment with HFSG, not to become associated with any entity, whether as a
principal, partner, employee, agent, consultant, shareholder (other than as a holder, or a
member of a group which is a holder, of not in excess of 1% of the outstanding voting
            shares of any publicly traded company) or in any other relationship or capacity, paid or
unpaid, that is actively engaged in any geographic area in any insurance or financial
services business which is in competition with the business of HFSG or its affiliates.
Anything herein to the contrary you shall not be precluded from becoming associated with a
financial services entity which conducts insurance business if its revenues attributable to
the insurance business amount to less than 20% of the entity’s total revenues for the last
completed fiscal year, provided that you are not directly managing the insurance business.
HFSG shall carefully consider a request that this provision be waived, but retains the
right, in its sole discretion, to enforce or waive the terms of this provision consistent
with its determination of its business needs, and

(b) while employed by HFSG and for a one year period following termination of your
employment with HFSG, not to directly or indirectly solicit, encourage or induce any
employee of HFSG or its affiliates to terminate employment with such entity, and not to
directly or indirectly, either individually or as owner, agent, employee, consultant or
otherwise, employ or offer employment to any person who is or was employed by HFSG or an
affiliate thereof unless such person shall have ceased to be employed by such entity for a
period of at least six months.

11. Confidentiality. Without the prior written consent of HFSG, except to the extent required
by an order of a court having competent jurisdiction or under subpoena from an appropriate
government agency, you agree that you shall not disclose to any third person, or permit the use of
for the benefit of any person or any entity other than HFSG or its affiliates, any trade secrets,
customer lists, information regarding product development, marketing plans, sales plans, management
organization information (including data and other information relating to members of the Board and
management), operating policies or manuals, business plans, financial records, or other financial,
organizational, commercial, business, sales, marketing, technical, product or employee information
relating to HFSG or its affiliates or information designated as confidential, proprietary, and/or a
trade secret, or any other information relating to HFSG or its affiliates that you know from the
circumstances, in good faith and good conscience, should be treated as confidential, or any
information that HFSG or its affiliates may receive belonging to customers, agents or others who do
business with HFSG or its affiliates, except to the extent that any such information previously has
been disclosed to the public by HFSG or is in the public domain. You acknowledge and agree that
this confidentiality obligation shall survive your termination of employment with HFSG.

12. Equitable Relief. You acknowledge and agree that the covenants and obligations in
paragraphs 10 and 11 with respect to noncompetition, nonsolicitation and confidentiality relate to
special, unique and extraordinary matters and that, given the extensive knowledge of HFSG’s
operations that you will acquire, a violation of any of the terms of these covenants and
obligations will cause HFSG irreparable injury for which adequate remedies are not available at
law. Therefore, you agree that HFSG shall be entitled to an injunction, restraining order or such
other equitable relief (without the requirement to post bond) restraining you from committing any
violation of the covenants and obligations contained in paragraphs 10 and 11, and that HFSG and its
affiliates shall, to the extent consistent with EESA and other applicable law, have no obligation
to pay any amounts to you following any material violation of the covenants and obligations
contained in those paragraphs. These remedies are cumulative and are in addition to any other
rights and remedies HFSG may have at law or in equity.

13. Dispute Resolution. This letter agreement shall be governed by the laws of the State of
Connecticut, without reference to principles of conflicts or choice of law under which the law of
any other jurisdiction would apply. In the event that one or more of the provisions of this letter
agreement shall become invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein shall not be affected thereby. In the
event of a determination that any of the provisions of paragraphs 10 or11 are not enforceable in
accordance with their terms, you and HFSG agree that those provisions shall be reformed to make the
provisions enforceable in a manner that provides HFSG the maximum rights permitted at law. Except
as provided in paragraph 12, any dispute or controversy arising under or in connection with this
letter agreement shall be resolved by binding arbitration, to be held in the city of Hartford,
Connecticut and conducted in accordance with the Commercial Arbitration Rules of the American
Arbitration Association in effect at the time of the arbitration, and otherwise in accordance with
the principles that would be applied by a court of law or equity.

14. Compliance with EESA. Notwithstanding anything to the contrary in this letter agreement,
all compensation payable to you by HFSG under this letter agreement or otherwise shall be limited
to the extent required by EESA and other applicable law.

We look forward to your leadership of the company.

Sincerely,

THE HARTFORD FINANCIAL SERVICES GROUP, INC.

By: /s/ Charles B. Strauss 

Charles B. Strauss 

I agree with and accept the foregoing terms.

       /s/ Liam E. McGee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]